Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous hematopoietic stem cells (non-cryopreserved) refer to a cell therapy product where a patient's own peripheral blood stem cells (PBSCs) or bone marrow are collected via apheresis and stored at refrigerated temperatures (typically +4°C to +6°C) for a short duration (72-120 hours) instead of being frozen with cryoprotectants like dimethyl sulfoxide (DMSO). This approach is primarily utilized in autologous hematopoietic stem cell transplantation (auto-HSCT) for hematologic malignancies such as multiple myeloma. By avoiding cryopreservation, the procedure eliminates the need for specialized cryobanking infrastructure and reduces infusion-related toxicities associated with DMSO, such as nausea, vomiting, and cardiovascular symptoms, while maintaining similar engraftment kinetics and therapeutic efficacy compared to traditional cryopreserved grafts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous hematopoietic stem cells (non-cryopreserved).